Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by on Jul 16th, 2026

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $7.5312.

Several research analysts have weighed in on PRME shares. Wall Street Zen lowered shares of Prime Medicine from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 13th. New Street Research set a $8.00 price target on shares of Prime Medicine in a research report on Monday, June 29th. TD Cowen reiterated a “buy” rating on shares of Prime Medicine in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a report on Wednesday, June 3rd. Finally, HC Wainwright upgraded Prime Medicine from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Monday, June 29th.

Get Our Latest Stock Analysis on PRME

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Chelsea Counsel Co. grew its position in shares of Prime Medicine by 103.7% during the 1st quarter. Chelsea Counsel Co. now owns 462,340 shares of the company’s stock valued at $1,609,000 after buying an additional 235,340 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Prime Medicine in the first quarter worth $6,867,000. Royal Bank of Canada lifted its stake in Prime Medicine by 89.3% in the first quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after buying an additional 4,365 shares during the last quarter. Redmile Group LLC bought a new stake in Prime Medicine in the first quarter valued at $5,536,000. Finally, Sei Investments Co. acquired a new position in shares of Prime Medicine during the first quarter valued at $102,000. 70.37% of the stock is currently owned by institutional investors.

Prime Medicine Stock Up 0.3%

PRME stock opened at $3.48 on Thursday. Prime Medicine has a 52-week low of $2.67 and a 52-week high of $6.94. The stock’s 50 day moving average is $3.30 and its two-hundred day moving average is $3.58. The company has a market capitalization of $628.56 million, a PE ratio of -2.83 and a beta of 2.26.

Prime Medicine (NASDAQ:PRME – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The business had revenue of $0.86 million for the quarter. Prime Medicine had a negative net margin of 4,917.55% and a negative return on equity of 188.82%. As a group, sell-side analysts anticipate that Prime Medicine will post -0.98 EPS for the current year.

About Prime Medicine

(Get Free Report)

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.

Featured Articles

Analyst Recommendations for Prime Medicine (NASDAQ:PRME)

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.